Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Qing Zhou(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jiuwei Cui(Jilin University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), Hai‐Yan Tu(Jiangnan University), Nong Yang(Central South University), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Xiaoling Li(University of Science and Technology of China), Zhen Wang(Guangdong Academy of Medical Sciences), Yong Song(Nanjing General Hospital of Nanjing Military Command), Jin‐Ji Yang(Guangdong General Hospital), Shiying Yu(Dalian Ocean University), Yongqian Shu(Jiangsu Province Hospital), Cheng Huang(Army Medical University), Yunpeng Liu(Shenyang Institute of Automation), Gongyan Chen(Harbin Medical University), Shun Lü(Shanghai Jiao Tong University), Zhiyong Ma(Zhengzhou University), Chong‐Rui Xu(Guangdong Academy of Medical Sciences)
Cancer Cell
August 12, 2021
10.1016/j.ccell.2021.07.005
Cited by 232

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k